News headlines about Corbus Pharmaceuticals (NASDAQ:CRBP) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Corbus Pharmaceuticals earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.7720338025474 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the media stories that may have effected Accern’s analysis:
- Investor’s Alert (Technicals Data Analysis) – Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) – The Investor Guide (wallstreetnews24.com)
- Cannabis Market Sales on the Rise According to Data (medindia.net)
- Cannabis Market Sales on the Rise According to Data – PR Newswire (press release) (prnewswire.com)
- Stock’s Technical Levels under Review – Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) – The Investor Guide (wallstreetnews24.com)
A number of equities analysts recently weighed in on the stock. Cantor Fitzgerald set a $28.00 target price on shares of Corbus Pharmaceuticals and gave the stock an “overweight” rating in a research report on Thursday, December 14th. BidaskClub downgraded shares of Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, December 20th. Finally, Noble Financial restated a “buy” rating on shares of Corbus Pharmaceuticals in a report on Saturday, December 23rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. Corbus Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $25.00.
Corbus Pharmaceuticals (NASDAQ:CRBP) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. The business had revenue of $0.80 million for the quarter. Corbus Pharmaceuticals had a negative net margin of 1,040.41% and a negative return on equity of 96.02%. equities analysts expect that Corbus Pharmaceuticals will post -0.6 EPS for the current year.
In other news, Director David P. Hochman bought 5,000 shares of the business’s stock in a transaction dated Monday, November 13th. The stock was purchased at an average cost of $6.90 per share, with a total value of $34,500.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director David P. Hochman bought 10,000 shares of the business’s stock in a transaction dated Friday, November 10th. The shares were purchased at an average cost of $7.08 per share, with a total value of $70,800.00. Following the completion of the acquisition, the director now owns 459,500 shares in the company, valued at $3,253,260. The disclosure for this purchase can be found here. Insiders purchased a total of 25,336 shares of company stock valued at $175,632 over the last ninety days. 11.90% of the stock is currently owned by insiders.
ILLEGAL ACTIVITY NOTICE: This piece was first published by BBNS and is the property of of BBNS. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://baseballnewssource.com/markets/corbus-pharmaceuticals-crbp-earning-somewhat-positive-news-coverage-report-shows/1813875.html.
About Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with our FREE daily email newsletter.